RxDoctor Payments Data

Matthew Varner, DO

Pulmonary Disease · Columbia, SCNPI 1336522135

Payments from drug & device makers

$9,138in general payments, 2019–2025

Across 116 payments — averaging $78.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$4K
  • Noah Medical Corporation$1K
  • Medical Device Business Services, Inc.$1K
  • Johnson & Johnson$480
  • Inari Medical, Inc.$464
  • AstraZeneca$362
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$2002%
  • Travel & lodging$4,54250%
  • Food & beverage$4,36248%
  • Education$340%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,138 in reported general payments places this provider in the 65th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$197,870
Medicare patients
489
Services billed
1,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NucalaMepolizumab169$604,914
Dupixent PenDupilumab102$360,906
Tyvaso DpiTreprostinil13$305,043
Trelegy ElliptaFluticasone/Umeclidin/Vilanter368$285,133
TezspireTezepelumab-Ekko52$257,359
Breztri AerosphereBudesonide/Glycopyr/Formoterol66$54,880
Stiolto RespimatTiotropium Br/Olodaterol Hcl47$32,438
Tadalafil23$24,995
Spiriva RespimatTiotropium Bromide32$24,833
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr41$20,275
Breo ElliptaFluticasone/Vilanterol40$18,978
Bevespi AerosphereGlycopyrrolate/Formoterol Fum25$13,906
Albuterol Sulfate HfaAlbuterol Sulfate281$9,349
SymbicortBudesonide/Formoterol Fumarate33$8,801
Fluticasone-SalmeterolFluticasone Propion/Salmeterol33$5,138

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$356$931,909631 claims
AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Symbicort$362$334,946176 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$16$57,27179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →